Logo Recognition by Consensus for Enabling Blockchain Implementations

J. L. D. L. R. Esteva,A. El-Fakdi,Victor Torres,Xesca Amengual

DOI: https://doi.org/10.3233/978-1-61499-806-8-257

Abstract:

What problem does this paper attempt to address?

Current status of immune checkpoint inhibitors for gastric cancer

Koji Kono,Shotaro Nakajima,Kosaku Mimura

DOI: https://doi.org/10.1007/s10120-020-01090-4

2020-05-28

Gastric Cancer

Abstract:Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis with ICI including nivolumab and pembrolizumab has been emerging as a novel treatment strategy for advanced gastric cancers (GC). In a meta-analysis for anti-PD-1/PD-L1 therapy in GC, the objective response rate was 12.0% and the disease control ratio was 34.7%. The ICI treatment in GC provided modest survival benefit and especially, anti-PD-1 treatment could improve the 12-month and 18-month overall survival rate and prolonged the duration of the response. Moreover, it is likely that anti-PD-1/PD-L1 therapy is more effective in subgroups with microsatellite instability-high, Epstein-Barr virus-positive or high mutation burden in advanced GC. The next steps for developing ICI in GC are mainly two challenges as follows. First is the identification of accurate biomarkers that can predict the response to ICI. The second challenge is the clinical development of combinatorial approaches to maximize the efficacy of ICI. In this review, recent advances in ICI for GC are discussed from a viewpoint of translational aspect including biomarkers and tumor microenvironment, and from a viewpoint of clinical aspects including combination therapies.

oncology,gastroenterology & hepatology
Research Progress of Immunotherapy for Gastric Cancer

Zhipeng Zhang,Ningning Liu,Mingyu Sun

DOI: https://doi.org/10.1177/15330338221150555

2023-04-13

Technology in Cancer Research & Treatment

Abstract:Technology in Cancer Research &Treatment, Volume 22, Issue , January-December 2023. Gastric cancer (GC) is one of the most common gastrointestinal tract cancers worldwide, which has high incidence and mortality rates and poor prognosis. Although multidisciplinary comprehensive therapies consisting of surgery, chemotherapy, radiotherapy, and targeted therapy have made great progress in GC treatment, a satisfactory curative effect still cannot be achieved in many circumstances, and the 5-year survival of patients with GC remains to be very low. In China, about 75% of patients with GC are diagnosed in the advanced stage and thus miss the opportunity of surgical resection. Although the conventional treatment of GC has improved the survival time of advanced patients to a certain extent, the clinical efficacy has encountered a bottleneck and cannot bring higher survival benefits to patients. With the development of immunologic and molecular biologic technologies, immunotherapy has gradually become a new essential treatment for GC, which has attracted extensive attention in the field of oncology. The US Food and Drug Administration (USFDA) and China Food and Drug Administration (CFDA) have approved a variety of immune-related drugs for the treatment of GC, and all of which have achieved good efficacy. In this review, we summarize the recent development in nonspecific enhancer therapy, adoptive immunocell therapy, tumor vaccine therapy, oncolytic virus therapy, and immune checkpoint inhibitor therapy, and their roles in the treatment of GC.

oncology
Immune Checkpoint Inhibitors for Treatment of Advanced Gastric or Gastroesophageal Junction Cancer: Current Evidence and Future Perspectives

Zhening Zhang,Tong Xie,Xiaotian Zhang,Changsong Qi,Lin Shen,Zhi Peng

DOI: https://doi.org/10.21147/j.issn.1000-9604.2020.03.02

2020-01-01

Chinese Journal of Cancer Research

Abstract:Despite the application of conventional therapies, the prognosis of advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) is still poor. In recent years, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer therapy. Emerging evidence support the feasibility of programmed cell death-1 (PD-1) and its ligand (PD-L1) inhibition in chemo-refractory GC/GEJC. Nivolumab and pembrolizumab have initially been approved in Japan and United States, respectively for the third-line treatment of progressive GC or GEJC. In March 2020, nivolumab has also been licensed in China for treating advanced GC/GEJC who received ≥2 lines of systemic therapies. Current studies are moving forward to the first-line application or focusing on combination strategies, though data are insufficient and disputable. In this review, we summarize the recently reported and ongoing clinical trials in ICIs for advanced GC/GEJC. Molecular characteristics and clinical implications of different tumor subtypes are also reviewed. We further discuss the safety profile and biomarkers for predicting the response of ICIs, which has guiding values in clinical practice.
Immunotherapy and combined treatment in gastric cancer

Ruqian Ji

DOI: https://doi.org/10.54254/2753-8818/27/20240718

2023-12-20

Abstract:Gastric Carcinoma (GC) ranks as the fifth inducing cause for cancer incidence, and its the fourth inducing reason for cancer-related mortality. Traditional treatments, which involve a combination of chemotherapy and surgical resection, often yield unfavorable prognoses for gastric cancer patients, especially for those with advanced stages or metastases. Immunotherapy has recently emerged as the significant focus in the treatment of advanced gastric cancer, particularly for patients with MSI-H/dMMR. Medications targeting PD-1, such as nivolumab and Keytruda, have gained marketing approval in recent years. Additionally, some biomarkers like HER2, FGFR, and VEGF have shown positive efficacy in clinical research. However, resistance to immunotherapy remains a significant challenge, and the effectiveness of these pharmaceuticals often lasts only about a year for patients suffering advanced gastric cancer. Consequently, theres a need to explore new immune checkpoint inhibitors and discover novel combination therapy approaches. This review is aimed at introducing several latest immune checkpoint inhibitors currently in clinical phases or in pre-clinical stages, alongside innovative combination strategies for treating gastric cancer.
Current Status and Clinical Research Progress of Immunotherapy for Advanced Gastric Cancer

Jiaxin Wang

DOI: https://doi.org/10.26689/par.v7i5.5245

2023-09-25

Proceedings of Anticancer Research

Abstract:Advanced gastric cancer is a common digestive system tumor, and its treatment has always been a difficult problem. In recent years, with the rapid development of immunotherapy, the treatment effect of advanced gastric cancer has been significantly improved. This article introduces the current status and clinical research progress of immune checkpoint inhibitors in advanced gastric cancer. Commonly used immunotherapy methods include chemical drug therapy, biological therapy, and gene therapy, among which the immune checkpoint inhibitors are currently one of the most popular immunotherapy methods, including nivolumab, pembrolizumab, and atezolizumab, which target programmed death ligand 1 (PD-L1) low expression (1%–49%) and PD-L1 high expression (≥50%). The results of clinical studies have shown that immunotherapy can significantly prolong the survival of patients with advanced gastric cancer while having lower toxic side effects and better tolerance. However, immunotherapy also has some problems, such as drug resistance and repeated infection. Future research directions include exploring new immunotherapy methods, combination therapy, and individualized therapy.
The New Era of Immunotherapy in Gastric Cancer

Shogo Takei,Akihito Kawazoe,Kohei Shitara

DOI: https://doi.org/10.3390/cancers14041054

2022-02-18

Cancers

Abstract:Immune checkpoint inhibitors (ICIs) such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies have prolonged survival in various types of malignancies, including advanced gastric cancer (AGC). Nivolumab, a monoclonal anti-PD-1 antibody, showed an improvement in overall survival at a later-line therapy in unselected AGC patients in the ATTRACTION-2 study or in combination with chemotherapy as first-line therapy in the global CheckMate-649 study. Another monoclonal anti-PD-1 antibody, pembrolizumab, showed single agent activity in tumors with high microsatellite instability or high tumor mutational burden. Furthermore, a recent KEYNOTE-811 study demonstrated significant improvement in response rate with pembrolizumab combined with trastuzumab and chemotherapy for HER2-positive AGC. Based on these results, ICIs are now incorporated into standard treatment for AGC patients. As a result of pivotal clinical trials, three anti-PD-1 antibodies were approved for AGC: nivolumab combined with chemotherapy as first-line treatment or nivolumab monotherapy as third- or later-line treatment in Asian countries; pembrolizumab for previously treated microsatellite instability-high (MSI-H) or tumor mutational burden-high AGC, or pembrolizumab combined with trastuzumab and chemotherapy for HER2-positive AGC in the United States; and dostarlimab for previously treated MSI-H AGC in the United States. However, a substantial number of patients have showed resistance to ICIs, highlighting the importance of the better selection of patients or further combined immunotherapy. This review focused on molecular and immunological profiles, pivotal clinical trials of ICIs with related biomarkers, and investigational immunotherapy for AGC.

oncology
HUMAN SPERM DNA DAMAGE IN THE CONTEXT OF ASSISTED REPRODUCTIVE TECHNIQUES

M. Youssry,B. Özmen,Y. Orief,K. Zohni,S. Al-Hasani

2007-07-10

Abstract:Fertilization involves direct interaction of the sperm and oocyte, fusion of the cell membranes and union of male and female gamete genomes. The completion of this process and subsequent embryo development depend in part on the inherent integrity of the sperm DNA. Sperm genome quality has been emphasized for several years as playing a major role in early embryogenesis. There is clinical evidence showing that human sperm DNA damage may adversely affect reproductive outcomes and that spermatozoa of infertile men possess substantially more DNA damage than do spermatozoa of fertile men. Testing DNA integrity may help selecting spermatozoa with intact DNA or with the least amount of DNA damage for use in assisted reproductive techniques (ARTs). This review will focus on how sperm DNA is organized, what causes sperm DNA damage and what impact this damage may have on reproductive outcome.
Immunotherapy of Gastric Cancer: Past, Future Perspective and Challenges

Jun Xie,Liping Fu,Jin Li

DOI: https://doi.org/10.1016/j.prp.2020.153322

2021-01-01

Abstract:Gastric cancer is considered as the third leading cause of deaths and the fifth most common cancers worldwide. Common treatment approaches include chemotherapy, radiation, gastric resection and targeted therapies. The emergence of gastric cancer immunotherapy has already shown some promising results and have altered the therapeutic procedures. Now, different combination therapies as well as novel immunotherapies targeting new molecules have been proposed. Despite ongoing investigations on the therapeutic options and significant advancements in this regard, the disease is poorly prognosed. In fact, limited therapeutic options and delayed diagnosis lead to the progression, dissemination and metastasis of the disease. Current immunotherapies are mostly based on cytotoxic immunocytes, monoclonal antibodies and gene transferred vaccines. The use of Immune checkpoint inhibitors (ICIs) have grown rapidly. In this review, we aimed to explore perspective and progression of different approaches of immunotherapy in the treatment of GC and the clinical outcomes reported so far. We also summarized the tumor immunosurveillance and tumor immunoescape.
Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA.

S. Toné,O. Takikawa,A. Habara-Ohkubo,A. Kadoya,R. Yoshida,R. Kido

DOI: https://doi.org/10.1093/NAR/18.2.367

IF: 14.9

1990-01-25

Nucleic Acids Research

Abstract:Indoleamine 2,3-dioxygenase (IDO), a tryptophan degrading length and encodes a protein containing 403 residues and having enzyme, is induced by interferons (IFNs) (1, 2). As a first step a molecular weight of 45,324. towards elucidating the mechanism of IDO induction by IFN's, we report here the primary structure of human IDO deduced from sequences of cDNA clones. These clones were isolated from a Xgtl 1 library prepared from poly (A) + RNA of IFN-y -treated HEL cells (Flow 2000) with a monoclonal antibody against IDO. The predicted amino acid sequence contained partial amino acid sequences (underlined letters) of endopeptidic digests of purified IDO protein. The open reading frame is 1209 nucleotides in
Advances and Key Focus Areas in Gastric Cancer Immunotherapy: A Comprehensive Scientometric and Clinical Trial Review (1999-2023).

Yao-Nan Li,Bin Xie,Ying Zhang,Ming-Hua He,Yang Xing,Dong-Mei Mu,Hong Wang,Rui Guo

DOI: https://doi.org/10.3748/wjg.v29.i40.5593

IF: 5.374

2023-01-01

World Journal of Gastroenterology

Abstract:BACKGROUND:Gastric cancer (GC) is the sixth most common cancer and third leading cause of cancer-related deaths worldwide. Current treatments mainly rely on surgery- and chemotherapy-based systemic; however, the prognosis remains poor for advanced disease. Recent studies have suggested that immunotherapy has significant potential in cancer therapy; thus, GC immunotherapy may improve quality of life and survival for patients with this disease.AIM:To provide a comprehensive overview of the knowledge structure and research hotspots of GC immunotherapy.METHODS:We conducted a bibliometric analysis of publications on immunotherapy related to GC in the Web of Science Core Collection database. We analyzed 2013 pub-lications from 1999 to February 1, 2023, using the VOSviewer and CiteSpace software. We assessed publication and citation distributions using the WoS platform and explored research countries, institutions, journals, authors, references, and keywords (co-occurrence, timeline view, and burst analysis). In addition, we examined 228 trials on immunotherapy, 137 on adoptive cell therapy, 274 on immune checkpoint inhibitors (ICIs), and 23 on vaccines from ClinicalTrials.gov and the International Clinical Trials Registry Platform. The Impact Index Per Article for the top ten high-cited papers collected from Reference Citation Analysis (RCA) are presented.RESULTS:Our bibliometric analysis revealed that the study of immunotherapy in GC has developed rapidly in recent years. China accounted for almost half the publications, followed by the United States. The number of publications in recent years has been growing continuously, and most institutions and authors with the most publications are from China. The main keywords or clusters identified were "tumor microenvironment", "adoptive immunotherapy", "dendritic therapy", and "microsatellite instability".CONCLUSION:Our analysis of 2013 publications indicated that immunotherapy for GC has led to several new developments in recent years. Considerable progress has been made in vaccinations, immune checkpoint therapy, and adoptive cellular therapy. In particular, ICIs and chimeric antigen receptor T-cells are novel options for the treatment of GC. We suggest that the combination of ICIs, chemotherapy, targeted therapy, and other immunotherapies should be the primary research direction in the future.
PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

Yingzi Zhang,Yan Yang,Yiran Chen,Wu Lin,Xiangliu Chen,Jin Liu,Yingying Huang,Haiyong Wang,Lisong Teng

DOI: https://doi.org/10.3389/fimmu.2022.1060497

IF: 7.3

2022-11-24

Frontiers in Immunology

Abstract:Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality worldwide. As the main breakthrough direction, the application of immune checkpoint inhibitors makes patients with GC have better prognosis, where PD-L1/PD-1 inhibitors in immunotherapy have good anti-tumor immune efficacy. Further understanding of the regulatory mechanism of PD-L1 in GC may bring substantial progress to the immunotherapy. In this review, we provide information on the endogenous and exogenous regulatory mechanisms of PD-L1 and its biological functions combined with current clinical trials of PD-L1/PD-1 inhibitors in GC. The malignant biological phenotypes caused by PD-L1 and the corresponding clinical combined treatment scheme have been reported. Identifying the biomarkers of the potential efficacy of immunotherapy and specifying the clinical immunotherapy scheme in combination with molecular characteristics of patients may maximize clinical benefits and better prognosis.

immunology
Therapeutic Immunomodulation in Gastric Cancer

Venu Akkanapally,Xue-Feng Bai,Sujit Basu

DOI: https://doi.org/10.3390/cancers16030560

2024-01-28

Cancers

Abstract:Gastric carcinoma, being one of the most prevalent types of solid tumors, has emerged as the third leading cause of death worldwide. The symptoms of gastric cancer (GC) are typically complex, which makes early detection challenging. Immune checkpoint inhibition has become the new standard targeted therapy for advanced or metastatic GC. It is currently being explored in various combinations, both with and without chemotherapy, across multiple therapies in clinical trials. Immunotherapy can stimulate immune responses in GC patients, leading to the destruction of cancer cells. Compared with traditional therapies, immunotherapy has shown strong effectiveness with tolerable toxicity levels. Hence, this innovative approach to the treatment of advanced GC has gained popularity. In this review, we have outlined the recent advancements in immunotherapy for advanced GC, including immune checkpoint inhibitors, cancer vaccines, vascular endothelial growth factor-A inhibitors, and chimeric antigen receptor T-cell therapy. Our current emphasis is on examining the immunotherapies presently employed in clinical settings, addressing the existing challenges associated with these therapeutic approaches, and exploring promising strategies to overcome their limitations.

oncology
Recent developments in immunotherapy for gastrointestinal tract cancers

Xiaoyi Chong,Yelizhati Madeti,Jieyuan Cai,Wenfei Li,Lin Cong,Jialin Lu,Liyang Mo,Huizhen Liu,Siyi He,Chao Yu,Zhiruo Zhou,Boya Wang,Yanshuo Cao,Zhenghang Wang,Lin Shen,Yakun Wang,Xiaotian Zhang

DOI: https://doi.org/10.1186/s13045-024-01578-x

IF: 28.5

2024-08-11

Journal of Hematology & Oncology

Abstract:The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. The role of immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become increasingly pivotal in the treatment of advanced and perioperative GI tract cancers. Currently, anti-PD-1 plus chemotherapy is considered as first-line regimen for unselected advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJC), mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), and advanced esophageal cancer (EC). In addition, the encouraging performance of claudin18.2-redirected chimeric antigen receptor T-cell (CAR-T) therapy in later-line GI tract cancers brings new hope for cell therapy in solid tumour treatment. Nevertheless, immunotherapy for GI tumour remains yet precise, and researchers are dedicated to further maximising and optimising the efficacy. This review summarises the important research, latest progress, and future directions of immunotherapy for GI tract cancers including EC, G/GEJC, and CRC.

oncology,hematology
Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review

Agata Poniewierska-Baran,Karolina Sobolak,Paulina Niedźwiedzka-Rystwej,Paulina Plewa,Andrzej Pawlik

DOI: https://doi.org/10.3390/ijms25126471

IF: 5.6

2024-06-13

International Journal of Molecular Sciences

Abstract:Due to its rapid progression to advanced stages and highly metastatic properties, gastric cancer (GC) is one of the most aggressive malignancies and the fourth leading cause of cancer-related deaths worldwide. The metastatic process includes local invasion, metastasis initiation, migration with colonisation at distant sites, and evasion of the immune response. Tumour growth involves the activation of inhibitory signals associated with the immune response, also known as immune checkpoints, including PD-1/PD-L1 (programmed death 1/programmed death ligand 1), CTLA-4 (cytotoxic T cell antigen 4), TIGIT (T cell immunoreceptor with Ig and ITIM domains), and others. Immune checkpoint molecules (ICPMs) are proteins that modulate the innate and adaptive immune responses. While their expression is prominent on immune cells, mainly antigen-presenting cells (APC) and other types of cells, they are also expressed on tumour cells. The engagement of the receptor by the ligand is crucial for inhibiting or stimulating the immune cell, which is an extremely important aspect of cancer immunotherapy. This narrative review explores immunotherapy, focusing on ICPMs and immune checkpoint inhibitors in GC. We also summarise the current clinical trials that are evaluating ICPMs as a target for GC treatment.

biochemistry & molecular biology,chemistry, multidisciplinary
Determination of intramyocardial blood flow with xenon 127: new radionuclide with potential intraoperative application.

S. Khuri,S. Karaffa,R. Kloner,E. Barsamian,T. Yasuda,D. Tow

DOI: https://doi.org/10.1016/S0022-5223(19)37801-8

IF: 6.439

1980-08-01

Journal of Thoracic and Cardiovascular Surgery

Abstract:
Therapeutic strategies for gastric cancer targeting immune cells: Future directions

Yan Zhao,Yuansong Bai,Meili Shen,Yapeng Li

DOI: https://doi.org/10.3389/fimmu.2022.992762

IF: 7.3

2022-09-23

Frontiers in Immunology

Abstract:Gastric cancer (GC) is a malignancy with a high incidence and mortality, and the emergence of immunotherapy has brought survival benefits to GC patients. Compared with traditional therapy, immunotherapy has the advantages of durable response, long-term survival benefits, and lower toxicity. Therefore, targeted immune cells are the most promising therapeutic strategy in the field of oncology. In this review, we introduce the role and significance of each immune cell in the tumor microenvironment of GC and summarize the current landscape of immunotherapy in GC, which includes immune checkpoint inhibitors, adoptive cell therapy (ACT), dendritic cell (DC) vaccines, reduction of M2 tumor-associated macrophages (M2 TAMs), N2 tumor-associated neutrophils (N2 TANs), myeloid-derived suppressor cells (MDSCs), effector regulatory T cells (eT regs ), and regulatory B cells (B regs ) in the tumor microenvironment and reprogram TAMs and TANs into tumor killer cells. The most widely used immunotherapy strategies are the immune checkpoint inhibitor programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1) antibody, cytotoxic T lymphocyte–associated protein 4 (CTLA-4) antibody, and chimeric antigen receptor T (CAR-T) in ACT, and these therapeutic strategies have significant anti-tumor efficacy in solid tumors and hematological tumors. Targeting other immune cells provides a new direction for the immunotherapy of GC despite the relatively weak clinical data, which have been confirmed to restore or enhance anti-tumor immune function in preclinical studies and some treatment strategies have entered the clinical trial stage, and it is expected that more and more effective immune cell–based therapeutic methods will be developed and applied.

immunology
Current status of immunotherapy in gastric cancer

Ke Ji,Jia-Fu Ji

DOI: https://doi.org/10.1007/s44178-023-00055-8

2023-01-01

Holistic Integrative Oncology

Abstract:Gastric cancer is one of the most common cancer with high mortality and morbilidity in East Asia, especially in China. In recent year, new treatment strategies for gastric cancer have developed. Immune check point inhibitors (ICIs) have been detected as a new standard treatment in Gastric cancer, which helped to improve the prognosis of patients with gastric cancer. Attempts to combine immunotherapy have become one of the research focuses. In this article, application of immunotherapy in neoadjuvant therapy and translational treatment of gastric cnacer are reviewed. Which is expected to be a reference for comprehensive treatment plan of accurate treatment methods for gastric cancer patients. In order to provide experiences and reference to develop individualized treatment of gastric cancer in clinical practice.
Current therapies and progress in the treatment of advanced gastric cancer

Hongyu Li,Ming Shen,Shihao Wang

DOI: https://doi.org/10.3389/fonc.2024.1327055

IF: 4.7

2024-02-26

Frontiers in Oncology

Abstract:Gastric cancer (GC) remains one of the most life-threatening disease worldwide with poor prognosis because of the absence of effective treatment and the delay in diagnosis. Due to the delay of diagnosis, a large proportion of GC patients are diagnosed as advanced GC, with extreme short lifespan. In the past few years, some pivotal progress and novel therapies was proposed, and conducted into clinical researches and practice. In this study, we summarized the development of several novel immunotherapy or targeted treatment modalities for advanced GC, including immune checkpoint inhibitors, anti-angiogenic therapy and cancer vaccines. Additionally, the advantage and potential weakness in each of these therapeutic methods are also listed. Finally, we discussed the promising research direction of advanced GC treatment, and the limitation in basic and clinical research of advanced GC, including the combination of immunotherapy and targeted therapy.

oncology
Research progress in targeted therapy and immunotherapy for gastric cancer

Xuewei Li,Jun Xu,Jun Xie,Wenhui Yang

DOI: https://doi.org/10.1097/cm9.0000000000002185

IF: 6.133

2022-09-08

Chinese Medical Journal

Abstract:Gastric cancer (GC) is one of the most common malignant tumors worldwide. Its incidence ranks the 5th among all malignant tumors globally, and it is the 3rd leading cause of death among patients with cancer. Surgical treatment is the first choice in clinical practice. However, targeted therapy, immunotherapy, and other treatment methods have also become research hotspots at home and abroad with the development of individualized precision therapy in recent years, besides traditional radiotherapy and chemotherapy. At present, targeted therapy and immunotherapy are methods used for treating GC, and they have important clinical application value and prospects. This study aimed to review the research progress of targeted therapy and immunotherapy for GC, focusing on its mechanism of action and related important clinical trials, hoping to provide references for the clinical treatment of GC.

medicine, general & internal
Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?

Rilan Bai,Naifei Chen,Tingting Liang,Lingyu Li,Zheng Lv,Xiaomin Lv,Jiuwei Cui

DOI: https://doi.org/10.3389/fonc.2020.00912

IF: 4.7

2020-07-21

Frontiers in Oncology

Abstract:Considering the limited progress of chemotherapy and targeted therapy in improving the generally disappointing outcomes of advanced gastric or gastroesophageal junction cancer (GC/GEJC), immunotherapies have been gradually developed and advanced into novel frontiers of treatment for advanced GC/GEJC. Nevertheless, the response to immunotherapy was not always satisfactory, and the emergence of resistance was unavoidable. These factors prompt the development of different combination therapies and predictive and prognostic biomarkers of efficacy to improve the outcomes of patients with advanced GC/GEJC and to overcome drug resistance. This article discusses the advances of immune monotherapy, multiple current and ongoing clinical trials of immune combination therapy, immune-related adverse events, and various biomarkers in GC/GEJC.

oncology

Logo Recognition by Consensus for Enabling Blockchain Implementations

Current status of immune checkpoint inhibitors for gastric cancer

Research Progress of Immunotherapy for Gastric Cancer

Immune Checkpoint Inhibitors for Treatment of Advanced Gastric or Gastroesophageal Junction Cancer: Current Evidence and Future Perspectives

Immunotherapy and combined treatment in gastric cancer

Current Status and Clinical Research Progress of Immunotherapy for Advanced Gastric Cancer

The New Era of Immunotherapy in Gastric Cancer

HUMAN SPERM DNA DAMAGE IN THE CONTEXT OF ASSISTED REPRODUCTIVE TECHNIQUES

Immunotherapy of Gastric Cancer: Past, Future Perspective and Challenges

Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA.

Advances and Key Focus Areas in Gastric Cancer Immunotherapy: A Comprehensive Scientometric and Clinical Trial Review (1999-2023).

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

Therapeutic Immunomodulation in Gastric Cancer

Recent developments in immunotherapy for gastrointestinal tract cancers

Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review

Determination of intramyocardial blood flow with xenon 127: new radionuclide with potential intraoperative application.

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

Current status of immunotherapy in gastric cancer

Current therapies and progress in the treatment of advanced gastric cancer

Research progress in targeted therapy and immunotherapy for gastric cancer

Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?